1. Responsible for identifying, evaluating, negotiating, and executing business transactions that add new products, programs, and technologies to Organon’s commercial portfolio and pipeline.2. Support the Women’s Health Franchise; Influence and develop BD strategy and execute global or pan-regional transactions that advance company’s growth objectives.

https://www.nuancepharma.com/Nuance is a Shanghai-based late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.Our world-class clinical and regulatory teams, visionary business development and integrated commercial platforms enable us to continuously accelerate the access of innovative treatments to patients.Since our inception in 2014, we have assembled a portfolio of several promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia. We have targeted these therapeutic areas based on the severity of the unmet medical needs, the size of the at risk patient population, and the emergence of innovative products worldwide.

Screening, identifying and conducting initial scientific evaluation of new business opportunities, and working closely with colleagues in the US and global business development teams. Utilizing available databases to scout new leads and recommending promising new databases and resources to the team. Effectively presenting Mitsubishi Tanabe as a preferred partner to all potential leads. Accomplishments:• Building and leveraging existing network to continuously identify new business opportunities in the CNS, autoimmune and rare diseases area.• Leading the cross-functional teams to conduct deep business and scientific analyses, working closely with marketing, sales, legal, R&D, CMC and other functions. Leveraging relationships and insights to fully support the due diligence process.• Leading the partnering process including participation in initial partnership, licensing negotiations.• Developing and seamlessly transition mature leads to the scientific group, and initiating the early stage collaboration in the gene therapy area.

Responsible for operational activities of global business development. Carrying out project selection and evaluation activities, assisting expert consultation activities, and establishing the company’s global business development process.Accomplishments;• Supported Simcere’s globalization strategy by analyzing the ANDA landscape in the US, identified >10 potential partners for the future ANDA application, and introduced international experts to upper management• Invited as a panelist by the Yale-China Forum program to discuss the international health care opportunities in China• Supported and coordinated the Sino-U.S. Startup Competition in Life Science sponsored by the Precision Med BioScikin• Participated in the $10M investment deal with an innovative biotech company• A member of the China—East/Central-Europe Hospital Cooperation Delegate: explored the potential collaboration with East/Central European health care organizationss.

Identifying, developing and managing new & existing client relationships. Planning and implementing business strategy across territory and specific key accounts (Merck, Eli-Lilly, Regeneron, BMS, etc). Knowledgably representing DisocveRx’s three core technologies in drug discovery and development. Scientific and technical expertise in the broad therapeutic area, especially in the immuno-oncology area (PD1, GITR etc).Accomplishments: • Tremendously boosted the sales in the biologics discovery /development accounts• Initiated the business partnership with 14 biotechnology/pharmaceutical companies within 2 years • Technical consulting to pharmaceutical companies in a broad drug discovery range, from HTS screening to QC Manufacture.• Provided technical advice in IND application, especially in the toxicology and translational medicine area. (Providing human primary cell platform to help clients confirm drug’s MOA/MOT, and predict the toxicity and efficacy).• Partnership with pharmaceutical companies in strategically building their oncology pipelines by providing functional cell based assays• Managing million-dollar projects with the international pharmaceutical companies

Identified and analyzed pharmaceutical/nutritional opportunities. Developed business relationship with potential investors and business partners. Accomplishments: • Developed the business strategic plan and compiled summary reports for funding applications.• Developed business relationship with angel/VC investors and international business partners.• Managed the project progress with multiple stakeholders including government officers, academic professors and potential business partners, etc.• Business/Technology consulting for portfolio development

(Contract from 2008 to 2009, converted to regular, full-time employee in September, 2009)Identified potential drug candidates for a variety of genetic mutation disorders. Synthesized novel compounds and collaborated with biologists and pharmacologists to assess the results. Optimized compound structures to improve activity and exposure and decrease toxicity. Conducted extensive Structure Activity Relationship (SAR) analyses to guide synthesis strategies. Analyzed, summarized and presented the project progress to cross-functional drug discovery teams and the advisory board members. Accomplishments: Spinal Muscular AtrophySynthesized more than 120 novel compounds and improved the potency 1000 times compared to the hit compound.Collaborated with patent attorneys to file three patents.Actively contributed to the $30 millions collaboration deal with RocheOncologySynthesized more than 400 novel compounds within 1 year Optimized the synthesis of an anti-cancer drug in clinical trials. Discovered and identified the compound's hidden isomers resulting in the enhancement of the potency by two times.

Developed bioanalytical assays to purify, identify and characterize enzyme SIRT1. Designed and synthesized small molecules in treating SIRT1-related aging diseases. Coordinated the collaboration with scientists from Harvard University (Dr. David Sinclair’s lab) to explore the metabolism of Nicotinamide Adenine Dinucleotide (NAD). Mentored junior scientists (2 Ph.D. students and 2 lab technicians).Accomplishments:Invented a MALDI-MS dependent methodology to detect the concentration of NAD in vivo and published the research in cell.Designed and internationally patented the synthesis of nicotinamide riboside and its derivatives.Managed and provided the custom synthesis service to external institutions and companies, which brought more collaboration and extra income for the entire lab.Published 8 articles, including reviews, in peer-reviewed journals.Educated the public about “anti-aging and calorie restriction” through public speeches.

Explored the DNA conformation modification by benzopyrene diol epoides. Synthesized malachite green and its metabolites for the metabolism study. Taught the chemistry lab for Pharm. D. students.Accomplishments:Optimized and completed an 18-step synthesis to stereoselectively prepare 2-F-benzopyrene diol epoxides.Discovered a novel chemistry to prepare diarylamines from ntitroarenes, and proposed possible mechanisms.Received several graduate student awards, including the highest award to graduate students in University of Rhode Island (URI), “ URI Graduate Fellowship Award”.